Grants Search Results

Based on progress to date, Dr. Hermiston was awarded a new grant in 2011 to fund an additional two years of this Scholar award. Almost all patients who have relapsed leukemia or lymphoma will die. Dr. Hermiston's research is to find a way to predict which of these patients with T-cell malignancies are likely to relapse, so those children can be given the aggressive treatments they need upon diagnosis, and those not likely to relapse can avoid the long-term side effects of unnecessarily aggressive treatments.

Based on progress to date, Dr. Janeway was awarded a new grant in 2011 to fund an additional two years of this Scholar award. Osteosarcoma is the most common primary bone tumor in children, yet 80% of metastatic cases remain incurable. (Metastatic means it has "spread" beyond the primary site, in this case the bones.) No therapeutic advances have been made for two decades. Dr. Janeway's research is to find drugs that cause osteosarcoma to act more like normal bone than like cancer; find ways to halt the progression to metastatic osteosarcoma; and develop a useful testing ground for drugs to treat metastatic osteosarcoma.